<DOC>
	<DOCNO>NCT01582295</DOCNO>
	<brief_summary>This research study Phase I clinical trial . Phase I clinical trial test safety investigational drug . Phase I study also try define appropriate dose investigational drug use study . `` Investigational '' mean drug still study research doctor try find . It also mean FDA approve drug type cancer . Cabozantanib ( XL184 ) new drug develop treat cancer . The study drug cabozantinib work inhibit several different protein believe involved multiple myeloma growth , ability spread , ability form new blood vessel . This drug use research study information research study suggest drug may help slow stop disease growth bone prevent cancer growth . In research study , look see effective cabozantanib slow stop disease growth bone well prevent cancer worsen . We also look high dose cabozantinib give safely patient multiple myeloma bone disease .</brief_summary>
	<brief_title>XL184 For Relapsed/Refractory Multiple Myeloma ( MM ) With Bone Disease</brief_title>
	<detailed_description>Since look high dose study drug administer safely without severe unmanageable side effect participant multiple myeloma , everyone participates research study receive dose study drug . The dose get depend number participant enrol study well tolerated dos . The study drug , cabozantinib , come form tablet take mouth . You take dose cabozantinib day 28 day cycle . Detailed instruction take study drug food drink prohibit take research study find study drug diary . During Cycle 1 , come clinic weekly ( Day 1 , 8 , 15 22 ) . For cycle , come clinic Day 1 15 . A visit schedule 30 day finish stop take study drug doctor able check well .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Bone Diseases</mesh_term>
	<criteria>Relapsed/Refractory Multiple Myeloma Skeletal lesion suggestive bone involvement Must receive least 2 line prior systemic therapy treatment multiple myeloma Must receive prior treatment proteasome inhibitor Agree use medically accept barrier method contraception Not candidate ASCT , decline option relapse prior ASCT Pregnant breastfeeding Has receive radiotherapy thoracic cavity GI tract ( within 3 month first dose study drug ) , bone brain metastasis ( within 14 day first dose ) site ( within 28 day ) Has receive investigational agent within 28 day Primary brain tumor Uncontrolled , significant intercurrent recent illness Cardiovascular disorder ( ) Gastrointestinal disorder ( )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Bone disease</keyword>
</DOC>